Register for email alerts and news feeds:
This journal | BMJ Group
rss
Br J Sports Med. Published Online First: 13 February 2008. doi:10.1136/bjsm.2007.044628
Copyright © 2008 BMJ Publishing Group Ltd & British Association of Sport and Exercise Medicine.

Paper

Oral administration of the probiotic Lactobacillus fermentum VRI-003 and mucosal immunity in endurance athletes

Amanda J Cox 1, David B Pyne 1*, Philo U Saunders 1 and Peter Allen Fricker 1

1 Australian Institute of Sport, Australia

* To whom correspondence should be addressed. E-mail: david.pyne{at}ausport.gov.au.

Accepted 21 December 2007


Abstract

Objective: To evaluate the ability of a probiotic Lactobacillus fermentum VRI 003 (PCC) to enhance the mucosal immune system of elite athletes.

Design and Setting: A double-blind, placebo-controlled, cross-over trial was conducted over a four-month period of winter training.

Participants: 20 healthy elite male distance runners.

Interventions: PCC was given at a daily dose of 1.2x10^10 as a freeze dried powder in gelatin capsules. Placebo capsules contained an inert excipient.

Main Outcome Measures: Treadmill performance (monthly), mucosal and systemic immunity (monthly), training (daily), and illness (daily) were assessed. Serum cytokine levels, salivary IgA levels and incidence, duration and severity of respiratory tract infections.

Results: Subjects reported less than half the number of days of respiratory symptoms during PCC treatment (30 d) compared with placebo (72 d, p=0.00006). Illness severity was also lower for episodes occurring during the PCC treatment (p=0.06). There were no significant differences in the mean change in salivary IgA and IgA1 levels, or in interleukin IL-4 and interleukin-12 levels, between treatments. However, PCC treatment elicited a two-fold (p=0.07) greater change in whole-blood culture interferon gamma (IFN-fx) compared with placebo. There were no substantial changes in running performance measures over the study period.

Conclusions: Prophylactic administration of PCC was associated with a substantial reduction in the number of days and severity of respiratory illness in a cohort of highly trained distance runners. Maintenance of IFN-fx] levels may be one mechanism underpinning the positive clinical outcomes.

Key Words: distance running, immunity, probiotics, respiratory illness, supplement


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Citing Articles
Google Scholar
PubMed
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

 

The journal is co-owned by and the official journal of BASEM

Official journal of ECOSEP

Available online to all members of ACSP, AMSSM and SMNZ